Winnipeg, Manitoba — November 4, 2025 — Leads & Copy — Kane Biotech Inc. (TSX-V: KNE) announced new clinical and pre-clinical data demonstrating the performance of its FDA-cleared revyve® Antimicrobial Wound Gel and revyve Wound Gel Spray in diabetic foot ulcer healing and burn wound infection control.
The findings were recently presented at the Diabetic Foot Conference (DFCon 2025) in Anaheim, California, and the Southern Region Burn Conference in Charleston, South Carolina.
Clinical data presented at DFCon 2025 by Dr. Raymond Abdo and Dr. Peter Moyer showed revyve achieved healing outcomes exceeding the current standard of care for diabetic foot ulcers, with a 97% average Percent Area Reduction (PAR) in 4 weeks and complete wound closure within 8–12 weeks in all cases. Dr. Mack Drake presented pre-clinical data at the Southern Region Burn Conference demonstrating 99.99 – 99.9999% reduction in burn-associated pathogens within 30 minutes of application and sustained antibiofilm activity for 7 days.
According to Dr. Robert Huizinga, Interim CEO of Kane Biotech, these findings underscore revyve’s ability to improve upon the standard of care in both diabetic foot and burn management. The presentations can be found at The Reduction of High Bacterial loads in DFUs Using a New Thermo-Reversible Wound Gel Leads to Faster Healing Rates; A Case Series: A New Thermo-Reversible Wound Gel To Alter Wound Microbiome And Significantly Improve Patient Outcomes; A Case Series: >90% PAR In 2-4 Weeks: A New Thermoreversible Wound Gel For Treatment Of Diabetic Foot Ulcers; Antimicrobial and Antibiofilm Efficacies of a Thermo-Reversible Antimicrobial Wound Gel.
Dr. Robert Huizinga, Interim CEO, rhuizinga@kanebiotech.com, (780) 970-1100
Ray Dupuis, Chief Financial Officer, rdupuis@kanebiotech.com, (204) 298-2200
Source: Kane Biotech Inc.
